Cargando…

FGFR4 does not contribute to progression of chronic kidney disease

In chronic kidney disease (CKD), elevated serum levels of the phosphate regulating hormone fibroblast growth factor (FGF) 23 have emerged as powerful risk factors for cardiovascular disease and death. Mechanistically, FGF23 can bind and activate fibroblast growth factor receptor (FGFR) 4 independent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Ashlee, Yanucil, Christopher, Musgrove, John, Shi, Melody, Ide, Shintaro, Souma, Tomokazu, Faul, Christian, Wolf, Myles, Grabner, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773883/ https://www.ncbi.nlm.nih.gov/pubmed/31575945 http://dx.doi.org/10.1038/s41598-019-50669-0

Ejemplares similares

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)

FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes
por: Yanucil, Christopher, et al.
Publicado: (2022)

Yolk-sac-derived macrophages progressively expand in the mouse kidney with age
por: Ide, Shintaro, et al.
Publicado: (2020)

Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling
por: Czaya, Brian, et al.
Publicado: (2022)

Importance of Extra-Renal CYP24A1 Expression for Maintaining Mineral Homeostasis
por: Shi, Melody, et al.
Publicado: (2021)

Sex differences in resilience to ferroptosis underlie sexual dimorphism in kidney injury and repair
por: Ide, Shintaro, et al.
Publicado: (2022)

Twist1 in podocytes ameliorates podocyte injury and proteinuria by limiting CCL2-dependent macrophage infiltration
por: Ren, Jiafa, et al.
Publicado: (2021)

Ferroptotic stress promotes the accumulation of pro-inflammatory proximal tubular cells in maladaptive renal repair
por: Ide, Shintaro, et al.
Publicado: (2021)

UPDATE ON FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE
por: Wolf, Myles
Publicado: (2012)

FGFR1 variants contributed to families with tooth agenesis
por: Yao, Siyue, et al.
Publicado: (2023)

Renal erythropoietin-producing cells in health and disease
por: Souma, Tomokazu, et al.
Publicado: (2015)

Contribution of FGFR1 Variants to Craniofacial Variations in East Asians
por: Adel, Mohamed, et al.
Publicado: (2017)

Current progress in cancer treatment by targeting FGFR signaling
por: Du, Sicheng, et al.
Publicado: (2023)

Aberrations in FGFR1, FGFR2, and RIP5 Expression in Human Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)
por: Kelam, Nela, et al.
Publicado: (2022)

Does erythropoietin slow progression of chronic kidney disease?
por: Nasri, Hamid, et al.
Publicado: (2013)

Plasma Serotonin and Cardiovascular Outcomes in Chronic Kidney Disease
por: Edmonston, Daniel, et al.
Publicado: (2023)

Activated FGFR3 contributes to cancer in a context-dependent manner
Publicado: (2011)

Impact of FGFR4 Gene Polymorphism on the Progression of Colorectal Cancer
por: Shiu, Bei-Hao, et al.
Publicado: (2021)

Does hypokalemia contribute to acute kidney injury in chronic laxative abuse?
por: Lee, Eun-Young, et al.
Publicado: (2015)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
por: Gao, Lixia, et al.
Publicado: (2017)

Immunohistochemical Expression Pattern of FGFR1, FGFR2, RIP5, and HIP2 in Developing and Postnatal Kidneys of Dab1(−/−) (yotari) Mice
por: Kelam, Nela, et al.
Publicado: (2022)

TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer
por: Kawahara, Takashi, et al.
Publicado: (2019)

FGFR1 and WT1 are markers of human prostate cancer progression
por: Devilard, Elizabeth, et al.
Publicado: (2006)

The interplay between NCAM and FGFR signalling underlies ovarian cancer progression
por: Colombo, N, et al.
Publicado: (2011)

FGFR1 amplification and the progression of non-invasive to invasive breast cancer
por: Gru, Alejandro A, et al.
Publicado: (2012)

FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
por: Jang, Min Hye, et al.
Publicado: (2012)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Olfactory receptors contribute to progression of kidney fibrosis
por: Motahharynia, Ali, et al.
Publicado: (2022)

DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
por: Chen, Xin, et al.
Publicado: (2022)

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
por: Subbiah, Vivek, et al.
Publicado: (2023)

FGFR4 Gly(388)Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls
por: Xu, Bin, et al.
Publicado: (2011)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling
por: Zecchini, Silvia, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_43dkut562m9s5puktp4doipdp1